{"disease":{"id":"limb-girdle-muscular-dystrophy","name":"limb girdle muscular dystrophy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04475926","title":"A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":205,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05102799","title":"MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06507215","title":"Dysferlinopathy Protein in Peripheral Blood Monocytes.","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT03981289","title":"Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT04202627","title":"Biomarker Development in LGMD2i","phase":"","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"ML Bio Solutions, Inc.","has_results":false},{"nct_id":"NCT03488784","title":"Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Lindsay Alfano","has_results":false},{"nct_id":"NCT06399770","title":"The Role of Muscle Ultrasound in Assessment of Sample of Patients With Limb-girdle Muscular Dystrophy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05956132","title":"Clinical and Biochemical Features for the Identification of Dominant Calpainopathies","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"IRCCS San Camillo, Venezia, Italy","has_results":false},{"nct_id":"NCT05528757","title":"Limb-Girdle Video Assessment","phase":"","overall_status":"TERMINATED","enrollment_count":45,"lead_sponsor_name":"The Emmes Company, LLC","has_results":false},{"nct_id":"NCT04349566","title":"Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Mads Peter Godtfeldt Stemmerik","has_results":false},{"nct_id":"NCT05409079","title":"Schulze Muscular Dystrophy Ability Clinical Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"AbiliTech Medical Inc.","has_results":false},{"nct_id":"NCT03492346","title":"Limb Girdle Muscular Dystrophy Type 2E Recruitment Study","phase":"","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT06390566","title":"Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04054375","title":"Weekly Steroids in Muscular Dystrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT02579239","title":"Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"aTyr Pharma, Inc.","has_results":true},{"nct_id":"NCT06246513","title":"A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05206617","title":"3 Year Follow up on ANO5 Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03783923","title":"A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT06378203","title":"Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI]","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"IRCCS Eugenio Medea","has_results":false},{"nct_id":"NCT02836418","title":"Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"aTyr Pharma, Inc.","has_results":true},{"nct_id":"NCT03652259","title":"Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05876780","title":"A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01976091","title":"A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06747273","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05906251","title":"A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}